News & Press Releases

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

DehydraTECH clinical test article manufacturing has been completed

DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use

DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively.

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups 

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups 

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups

Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”) and will expire five years from the Stockholder Approval Date.  

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format

KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the "Stockholder Approval Date") and will expire five years from the Stockholder Approval Date.

KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the "Stockholder Approval Date") and will expire five years from the Stockholder Approval Date. The closing of the offering is expected to occur on or about October 16, 2024, subject to the satisfaction of customary closing conditions.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Wednesday morning that dosing has begun for human pilot study #3. The study aims to investigate a DehydraTECH-processed version of Zepbound(R) (tirzepatide), the dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in oral dose format.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery technology, is sharing an update covering recent advancements in the glucagon-like peptide-1 (“GLP-1”) receptor agonist market. According to the report, the space has seen “unprecedented growth” and is “growing faster than nearly all historic forecasts had predicted.”

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has appointed Michael Shankman, CPA, as Chief Financial Officer (“CFO”) effective immediately. Mr. Shankman is deeply familiar with Lexaria, having previously worked with the company and assisted with its financial reporting and 2023 audit as a designated contractor. He has previously held financial leadership positions in various industries, including biotechnology, medical devices, and software-as-a-service.

KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands.